- Home
- MIST
as of 03-06-2026 3:41pm EST
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
| Founded: | 2003 | Country: | Canada |
| Employees: | N/A | City: | MONTREAL |
| Market Cap: | 176.3M | IPO Year: | 2019 |
| Target Price: | $8.50 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.60 | EPS Growth: | 51.80 |
| 52 Week Low/High: | $0.63 - $3.06 | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -2.66 | Index: | N/A |
| Free Cash Flow: | -28881000.0 | FCF Growth: | N/A |
AI-Powered MIST Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Milestone Pharmaceuticals Inc. (MIST)
Chief Commercial Officer
Avg Cost/Share
$1.93
Shares
11,180
Total Value
$21,577.40
Owned After
205,406
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$1.93
Shares
12,245
Total Value
$23,632.85
Owned After
113,181
SEC Form 4
President and CEO
Avg Cost/Share
$1.93
Shares
34,523
Total Value
$66,629.39
Owned After
482,744
SEC Form 4
Chief Operating Officer
Avg Cost/Share
$1.93
Shares
12,245
Total Value
$23,632.85
Owned After
49,848
SEC Form 4
CFO & EVP of Corp. Development
Avg Cost/Share
$1.93
Shares
12,245
Total Value
$23,632.85
Owned After
99,848
SEC Form 4
President and CEO
Avg Cost/Share
$2.25
Shares
43,000
Total Value
$96,750.00
Owned After
482,744
SEC Form 4
President and CEO
Avg Cost/Share
$2.25
Shares
500
Total Value
$1,125.00
Owned After
482,744
SEC Form 4
Chief Commercial Officer
Avg Cost/Share
$2.32
Shares
53,566
Total Value
$124,273.12
Owned After
205,406
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$2.32
Shares
58,007
Total Value
$134,576.24
Owned After
113,181
SEC Form 4
President and CEO
Avg Cost/Share
$2.32
Shares
133,054
Total Value
$308,685.28
Owned After
482,744
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Muller Lorenz | MIST | Chief Commercial Officer | Jan 26, 2026 | Sell | $1.93 | 11,180 | $21,577.40 | 205,406 | |
| Bharucha David | MIST | Chief Medical Officer | Jan 26, 2026 | Sell | $1.93 | 12,245 | $23,632.85 | 113,181 | |
| Oliveto Joseph | MIST | President and CEO | Jan 26, 2026 | Sell | $1.93 | 34,523 | $66,629.39 | 482,744 | |
| Nelson Jeffrey Edward | MIST | Chief Operating Officer | Jan 26, 2026 | Sell | $1.93 | 12,245 | $23,632.85 | 49,848 | |
| Hasija Amit | MIST | CFO & EVP of Corp. Development | Jan 26, 2026 | Sell | $1.93 | 12,245 | $23,632.85 | 99,848 | |
| Oliveto Joseph | MIST | President and CEO | Jan 8, 2026 | Sell | $2.25 | 43,000 | $96,750.00 | 482,744 | |
| Oliveto Joseph | MIST | President and CEO | Jan 7, 2026 | Sell | $2.25 | 500 | $1,125.00 | 482,744 | |
| Muller Lorenz | MIST | Chief Commercial Officer | Dec 15, 2025 | Sell | $2.32 | 53,566 | $124,273.12 | 205,406 | |
| Bharucha David | MIST | Chief Medical Officer | Dec 15, 2025 | Sell | $2.32 | 58,007 | $134,576.24 | 113,181 | |
| Oliveto Joseph | MIST | President and CEO | Dec 15, 2025 | Sell | $2.32 | 133,054 | $308,685.28 | 482,744 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q3 Q3 2025 Earnings
8-K BUY Nov 12, 2025 · 100% conf.
Q3 2025 Earnings
8-K BUYNov 12, 2025 · 100% conf.
1D
+4.83%
$2.02
5D
+7.52%
$2.08
20D
+19.64%
$2.31
false 0001408443 A8 00-0000000 QC
0001408443
2025-11-12 2025-11-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 12, 2025
MILESTONE
PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)
Québec
001-38899
Not applicable
(state or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
1111 Dr. Frederik-Philips Boulevard,
Suite 420
Montréal, Québec CA
H4M 2X6
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including area code: (514) 336-0444
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which
registered
Common Shares
MIST
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02. Results of Operations and Financial Condition.
On November 12, 2025, Milestone Pharmaceuticals Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2025, which also provided a regulatory and corporate update. A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
No.
Description
99.1
Press Release, dated November 12, 2025
104
Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MILESTONE PHARMACEUTICALS INC.
By: /s/Amit Hasija
Amit Hasija
Chief Financial Officer
Dated: November 12, 2025
2025 Q2 Q2 2025 Earnings
8-K Aug 12, 2025
Q2 2025 Earnings
8-KAug 12, 2025
false 0001408443 A8 00-0000000 QC
0001408443
2025-08-12 2025-08-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 12, 2025
MILESTONE
PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)
Québec
001-38899
Not applicable
(state or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
1111 Dr. Frederik-Philips Boulevard,
Suite 420
Montréal, Québec CA
H4M 2X6
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including area code: (514) 336-0444
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which
registered
Common Shares
MIST
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02. Results of Operations and Financial Condition.
On August 12, 2025, Milestone Pharmaceuticals Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2025, which also provided a regulatory and corporate update. A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
No.
Description
99.1
Press Release, dated August 12, 2025
104
Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MILESTONE PHARMACEUTICALS INC.
By: /s/Amit Hasija
Amit Hasija
Chief Financial Officer
Dated: August 12, 2025
2025 Q1 Q1 2025 Earnings
8-K May 14, 2025
Q1 2025 Earnings
8-KMay 14, 2025
false 0001408443 A8 00-0000000 QC
0001408443
2025-05-14 2025-05-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 14, 2025
MILESTONE
PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)
Québec
001-38899
Not applicable
(state or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
1111 Dr. Frederik-Philips Boulevard,
Suite 420
Montréal, Québec CA
H4M 2X6
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including area code: (514) 336-0444
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which
registered
Common Shares
MIST
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02. Results of Operations and Financial Condition.
On May 14, 2025, Milestone Pharmaceuticals Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2025, which also provided a regulatory and corporate update. A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
No.
Description
99.1
Press Release, dated May 14, 2025
104
Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MILESTONE PHARMACEUTICALS INC.
By: /s/Amit Hasija
Amit Hasija
Chief Financial Officer
Dated: May 14, 2025
Compare MIST vs Leading Stocks
See how MIST stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "MIST Milestone Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.